Kazakhstan changes the list of medicines purchased from the Single Distributor
The Minister of Health of the Republic of Kazakhstan, by order dated June 18, 2025, amended the list of medicines and medical products purchased from the Single Distributor.
The following are excluded from the list:
Silicones, drops for oral administration (emulsion) 40 mg;
Human insulin, 100 units/ml solution in 3 ml cartridges, complete with syringe pens at the rate of 50 cartridges 1 syringe pen, 100 units/ml solution in vials, 10 ml, short-acting;
Insulin lispro, solution 100 units/ml in 3 ml cartridges complete with syringe pens at the rate of 50 cartridges 1 syringe pen with a step of 0.5 units;
Human insulin recombinant, suspension 100 units/ml in 3 ml cartridges complete with syringe pens at the rate of 1 syringe pen for 50 cartridges;
Human insulin, two-phase, genetically engineered (30/70);
Insulin detemir, solution 100 units/ml in 3 ml cartridges complete with syringe pens at the rate of 50 cartridges 1 syringe pen with a step of 0.5 units;
Alogliptin, tablets;
Nandrolone, oil solution for injection 50 mg/ml 1 ml;
Warfarin, tablet 5 mg;
Hemostatic sponge containing fibrinogen and thrombin;
Plasma coagulation factor VIII without indication for treatment of von Willebrand disease;
Iron sulfate, capsule not less than 100 mg;
Calcium chloride, injection solution 10% 5 ml;
Hydrochlorothiazide, tablet 100 mg;
Eprosartan, tablet 600 mg;
Irbesartan, tablet 75 mg;
Isotretinoin, capsule 16 mg;
Lanreotide, lyophilisate for the preparation of a prolonged-release suspension for intramuscular administration 30 mg;
Cefuroxime, granules for preparation of oral suspension 125 mg/5 ml;
Cefixime, capsule 400 mg;
Midecamycin, granules for preparation of oral suspension 175 mg/5 ml, 20 g;
Kanamycin, powder for solution for injection 1000 mg;
Nitrofurantoin, tablet 50 mg;
Isoniazid, injection solution 10%, 5 ml;
Abacavir, oral solution 20 mg/ml, 240 ml (patients from the Turkestan region and Shymkent city with HIV infection take medications from one manufacturer throughout their lives);
Vinblastine, lyophilisate for solution 5 mg;
Ruxolitinib, tablet 20 mg;
Indomethacin, tablet 25 mg;
Diclofenac, tablet 25 mg, 100 mg;
Sodium thiopental, lyophilized powder for solution for injection 1000 mg;
Naltrexone, powder for preparation of prolonged-release suspension for intramuscular administration, 380 mg;
Vilanterol and umeclidinium bromide, dosed inhalation powder, 22 mcg/55 mcg;
Loratadine, syrup not less than 100 ml;
Natural phospholipids;
Metreleptin;
Phenytoin;
Glucose, solution for infusion 10% 400 ml;
Sodium chloride, solution for infusion 0.9% 250 ml;
Vaccine against human papillomavirus (types 6, 11, 16, 18), suspension for intramuscular administration 0.5 ml (1 dose) (From January 1, 2026);
Isotretinoin.
At the same time, the following drugs have been added to the list:
Tranexamic acid, injection solution 100 mg/ml;
Clevidipine, emulsion for intravenous administration, 0.5 mg/ml 50 ml;
Palivizumab, solution for intramuscular injection 50 mg;
Papillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52, 58), suspension for intramuscular injection 0.5 ml (1 dose);
Mitomycin, lyophilisate for preparation of solution for intravenous and intravesical administration, 40 mg;
Avelumab, concentrate for solution for infusion 20 mg/ml;
Aminolevulinic acid, powder for preparation of oral solution 1.5 g (with each unit of the drug, 1 unit of the drug is additionally provided free of charge);
Cabozantinib, tablet 20, 40, 60 mg;
Asparaginase, lyophilisate for the preparation of concentrate for the preparation of solution for infusions 10,000 IU (with each unit of the drug, 1 unit is additionally provided free of charge);
Bortezomib, lyophilisate for preparation of solution for intravenous and subcutaneous administration 2.5 mg;
Methotrexate, injection solution 25 mg/ml;
Nalbuphine, injection solution 10, 20 mg/ml;
Amantadine, solution for infusion 200 mg/500 ml;
Sodium levofolinate, solution for intravenous administration 50 mg/ml, 4 ml (complete with an outpatient infusion balloon system with a volume of at least 100 ml, a flow rate of 4.2 ml/hour, an infusion time of 24 hours, with a filter of no more than 0.2 μm)
Sodium levofolinate, solution for intravenous administration 50 mg/ml, 1 ml;
Macitentan, film-coated tablet, 10 mg.
In addition, the sterile container for bioassays, 120 ml, has been excluded from the list of medical products.
The order comes into effect on July 4, with the exception of the rule, which comes into effect on January 1, 2026. It can be found on the portal: https://pharmnewskz.com/ru/legislation/prikaz-ministra-zdravoohraneniya-rk-ot-18-iyunya-2025-goda--392_10260